Method and compositions for treating decreased cognitive ability

Abstract

Disclosed are methods and compositions for treating cognitive decline in subjects in need. More specifically, disclosed are methods of administrating exogenous adropin to subjects suffering from, or at risk of, cognitive decline including the aged and those suffering from traumatic brain injury. Also disclosed are subjects who would benefit from such treatment and pharmaceutical acceptable compositions comprising adropin, adropin34-76, and derivatives or variations thereof.

What is claimed is: 
     
         1 . A method of treating cognitive decline, in a subject in need, the method comprising administering an effective amount of (SEQ ID NO.:2) or (SEQ ID NO.:1), to the subject parenterally. 
     
     
         2 . The method of  claim 1 , wherein the subject in need is selected from the group consisting of a subject suffering from: traumatic brain injury, neurological trauma, neuroinflammation, and concussion. 
     
     
         3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein the effective amount is 1000 nmol/kg/day to about 1 nmol/kg/day. 
     
     
         5 . The method of  claim 1  wherein, an effective amount is about 450 nmol/kg/day. 
     
     
         6 . The method of  claim 1 , wherein the effective amount is about 90 nmol/kg/day. 
     
     
         7 . The method of  claim 1 , wherein the subject is a human subject. 
     
     
         8 . The method of  claim 1 , wherein the subject is a post-surgery or post brain injury, with symptoms of neuroinflammation. 
     
     
         9 . The method of  claim 1 , wherein the effective amount is administered one or more times within 24 hours of a traumatic brain injury event. 
     
     
         10 . The method of  claim 1 , wherein the effective amount is administered one or more times within 48 hours of a traumatic brain injury event. 
     
     
         11 . The method of  claim 1  wherein the effective amount is administered one or more times a day, over a period of 1 or more weeks. 
     
     
         12 . The method of  claim 1  wherein administering an effective amount consists of administering an oligonucleotide enabled to express (SEQ ID NO.:2) or (SEQ ID NO.:1). 
     
     
         13 . The method of  claim 1 , wherein, parenterally administration is selected from the group consisting of intraperitoneal, subcutaneous, intramuscular, and intravenous injection. 
     
     
         14 . The method of  claim 1 , further comprising a response from the subject wherein the subject's cognitive decline is arrested, reduced or slowed. 
     
     
         15 . (canceled) 
     
     
         16 . A method of treating traumatic brain injury, in a subject in need, the method comprising administering an effective amount of (SEQ ID NO.:2), (SEQ ID NO.:1), or variants or derivatives thereof, to the subject parenterally, wherein the subject's cognitive decline is arrested, reduced or slowed. 
     
     
         17 . The method of  claim 16 , wherein the variants or derivatives thereof, are polypeptides with conservative amino acid substitutes. 
     
     
         18 . The method of  claim 16 , wherein the variants or derivatives thereof, are polypeptides with 90 percent identity or greater. 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . The method of  claim 16 , wherein the effective amount of (SEQ ID NO.:2), (SEQ ID NO.:1), or variants or derivatives thereof, consists of (SEQ ID NO.:2). 
     
     
         24 . The method of  claim 16 , wherein the effective amount of (SEQ ID NO.:2), (SEQ ID NO.:1), or variants or derivatives thereof, consists of (SEQ ID NO.:1).